were found while preparing the Information Disclosure Statement which is submitted herewith. Applicants' amendments do not introduce new matter.

Respectfully submitted,

Dated: February 6, 2001

Virginia S. Medlen
Registration No. 32,050

Please direct all communications to:

Peter G. Carroll
Registration No.
MEDLEN & CARROLL, LLP
220 Montgomery Street, Suite 2200
San Francisco, California 94104
415/705-8410

APPENDIX I

PENDING CLAIMS AS AMENDED IN THIS COMMUNICATION

The following is a list of the claims as they would appear following entry of this amendment.

15. (Twice amended) A method for assessing overcoming synaptic vesicle glutamate uptake inhibition activity, comprising:

a) providing:

i) synaptic vesicles,

ii) a composition comprising a purified fodrin fragment having glutamate uptake inhibition activity, said fragment having an N-terminus and a C-terminus, and

iii) a candidate compound; and

b) combining said candidate compound with said synaptic vesicles and said fragment such that the effect of said candidate compound on glutamate uptake by said synaptic vesicles can be assessed.

16. The method of Claim 15, wherein said purified fragment comprises IPF α.

17. The method of Claim 15, wherein said purified fragment comprises IPF β.

18. The method of Claim 15, wherein said purified fragment comprises IPF γ.

19. (Twice Amended) A method for assessing overcoming synaptic vesicle glutamate uptake inhibition activity, comprising:

a) providing:

i) synaptic vesicles,

ii) a composition comprising a purified fragment of IPF having synaptic vesicle glutamate uptake inhibition activity, said fragment having an N-terminus and a C-terminus, and

iii) a candidate compound; and

b) combining said candidate compound with said synaptic vesicles and said purified fragment such that the effect of said candidate compound on said fragment's effect on glutamate uptake by said synaptic vesicles can be assessed.

---

20. The method of Claim 19, wherein said fragment comprises a fragment of IPF α.

21. The method of Claim 19, wherein said fragment comprises a fragment of IPF β.

22. The method of Claim 19, wherein said fragment comprises a fragment of IPF γ.

23. (New) The method of Claim 15, wherein said N-terminus is Tyr^{26} of fodrin.

24. (Once Amended) The method of Claim 15, wherein said purified fragment comprises a fragment of IPFα.

25. (New) The method of Claim 19, wherein said N-terminus is Tyr^{26} of fodrin.

26. (Once Amended) The method of Claim 19, wherein said purified fragment comprises a fragment of IPFα.

27. (Once Amended) A method for assessing overcoming synaptic vesicle glutamate uptake inhibition activity, comprising:

a) providing:

i) synaptic vesicles,

ii) a composition comprising a purified fragment of fodrin having glutamate uptake inhibition activity, said fragment having an N-terminus and a C-terminus, wherein said purified fragment comprises a peptide having the

amino acid sequence EAALTSEEVG within 150 amino acids of the C-terminus of the peptide, and

iii) a candidate compound; and

b) combining said candidate compound with said synaptic vesicles and said fragment such that the effect of said candidate compound on glutamate uptake by said synaptic vesicles can be assessed.

28. (Once Amended) A method for assessing overcoming synaptic vesicle glutamate uptake inhibition activity, comprising:

a) providing:

i) synaptic vesicles,

ii) a composition comprising a purified peptide having glutamate uptake inhibition activity with an N-terminus sequence comprising the amino acid sequence YHRFK, and

iii) a candidate compound; and

b) combining said candidate compound with said synaptic vesicles and said fragment such that the effect of said candidate compound on glutamate uptake by said synaptic vesicles can be assessed.

29. (New) The method of Claim 28, wherein said purified peptide has an N-terminus comprising the amino acid sequence YHRFKELSTL.

30. (New) The method of Claim 29, wherein said purified peptide has an N-terminus comprising the amino acid sequence YHRFKELSTLRRQKLEDSYR.